Indian Discovery Effort in the Quest of Novel Antibiotics

Process Development and Scale-Up of the Novel β-Lactamase Inhibitor WCK 6395

“…Scheme depicts the medicinal chemistry pathway for the synthesis of 1 from trans -4-hydroxy- l -proline (Hyp) . However, column chromatography was the best choice for (a) isolating semi-solid-natured 3 from the elimination byproduct 3a ; (b) purging triphenylphosphine oxide (TPPO) and 1,2-isopropylhydrazine dicarboxylate (DIAD-H 2 ) in the Mitsunobu reaction; (c) removing coupling reagent and byproducts; and (d) eliminating associated organic impurities of 9 .…”

“…Wockhardt Ltd has established a world-class antibiotic discovery research capability, with a pipeline of proprietary novel β-lactamase inhibitors (BLIs) that are either approved or in clinical development as potential drugs . In the past decade, the diazabicyclooctane (DBO) class of BLIs has expanded to include novel DBOs with modified chemical scaffolds that enhance their activity. , WCK 6395 , ( 1 , Figure ), a cyclic secondary amine of a pyrrolidine ring , with the advantage of fluorine, was identified as a potential oral drug candidate for complicated and uncomplicated urinary tract infections, community respiratory tract infections, and community-acquired Gram-negative infections.…”